Unbiased Lipidomic Profiling Reveals Metabolomic Changes during the Onset and Antipsychotics Treatment of Schizophrenia Disease
Abstract
Introduction Schizophrenia (SCH) is one of the most common psychiatric disorders, which involves impairments in motivation and cognition. The pathological mechanisms underlying SCH are still unknown, and no effective therapies can prevent or treat perfectly the cognitive impairments and deficit symptoms caused by SCH.Objectives We aimed to find the lipid expression change in plasma that underlie SCH onset and antipsychotics treatment.Methods We performed a data independent acquisition-based untargeted lipidomic approach on a quadrupole-time of flight liquid chromatography coupled to mass spectrometry platform. The plasma lipidomic profiles of SCH patients (n = 20) pre- and post-antipsychotics treatment were acquired as well as healthy controls (n = 29). Grouped or paired t-test were used to analyze the data.Results Over 1000 features were detected by our lipidomic analysis, of which 445 lipids belonging to 17 lipid species were reliably identified by tandem mass spectrometry. After statistical analysis, 47 lipids belonging to 9 lipid species were found to be dysregulated between naive SCH patients and healthy controls, and 50 lipids belonging to 9 lipid species were found to be dysregulated after antipsychotics treatment. These findings include several new SCH-relevant lipid species such as sphingomyelin, acylcarnitine and ceramide. Four types of lipid expression regulative patterns can be concluded from the above mentioned findings, revealing information about mechanism, side-effect and potential target of antipsychotics.Conclusions The work presented here have revealed several new lipid species which are significantly dysregulated in SCH disease development or antipsychotics treatment. These lipids provide new evidence for the pathological studies of SCH and new antipsychotics development, or can be considered as potentially candidate biomarkers for further validation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nine studies evaluated broad panels of different lipid markers in patients with SCZ and detected statistical differences in fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.
“Nine studies evaluated the broad panels of different lipid markers in patients with SCZ [31,34,40,41,42,43,44,45,46] and detected statistical differences in the following lipid classes: fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [42]
Cites
MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis
Tsugawa, H., Čajka, T., Kind, T., Ma, Y., Higgins, B. T., Ikeda, K., Kanazawa, M., VanderGheynst, J. S., Fiehn, O., & Arita, M. (2015) · Nature Methods · doi:10.1038/nmeth.3393 · Cited by 3,423 · see citing works
MetaboAnalyst 3.0—making metabolomics more meaningful
Xia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv380 · Cited by 2,680 · see citing works
Metabolomics: the apogee of the omics trilogy
Patti, G. J., Yanes, Ó., & Siuzdak, G. E. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3314 · Cited by 2,605 · see citing works
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394 · see citing works
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496 · see citing works
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291514 · Cited by 1,016 · see citing works
Translational biomarker discovery in clinical metabolomics: an introductory tutorial
Xia, J., Broadhurst, D., Wilson, M., & Wishart, D. S. (2012) · Metabolomics · doi:10.1007/s11306-012-0482-9 · Cited by 958 · see citing works
Metabolomics for Functional Genomics, Systems Biology, and Biotechnology
Saito, K., & Matsuda, F. (2009) · Annual Review of Plant Biology · doi:10.1146/annurev.arplant.043008.092035 · Cited by 749 · see citing works
Dendritic spine pathology in schizophrenia
Glausier, J. R., & Lewis, D. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.044 · Cited by 581 · see citing works
Scalbert, A., Brennan, L., Fiehn, O., Hankemeier, T., Kristal, B. S., van Ommen, B., Pujos-Guillot, E., Verheij, E., Wishart, D., & Wopereis, S. (2009) · Metabolomics · doi:10.1007/s11306-009-0168-0 · Cited by 565 · see citing works
Plumb, R. S., Johnson, K. A., Rainville, P. D., Smith, B. W., Wilson, I. D., Castro‐Perez, J. M., & Nicholson, J. K. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2550 · Cited by 486 · see citing works
An accelerated workflow for untargeted metabolomics using the METLIN database
Tautenhahn, R., Cho, K., Uritboonthai, W., Zhu, Z., Patti, G. J., & Siuzdak, G. E. (2012) · Nature Biotechnology · doi:10.1038/nbt.2348 · Cited by 474 · see citing works
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A., & Levitt, P. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000866 · Cited by 446 · see citing works
Morris, J. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg162 · Cited by 376 · see citing works
Gauthier, J., Champagne, N., Lafrenière, R. G., Xiong, L., Spiegelman, D., Brustein, E., Lapointe, M., Peng, H., Côté, M., Noreau, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906232107 · Cited by 369 · see citing works
Metabolomics: building on a century of biochemistry to guide human health
German, J. B., Hammock, B. D., & Watkins, S. M. (2005) · Metabolomics · doi:10.1007/s11306-005-1102-8 · Cited by 336 · see citing works
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M. S., Jakovčevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 328 · see citing works
Cannon, T. D., Thompson, P. M., van Erp, T. G. M., Toga, A. W., Poutanen, V.-P., HUTTUNEN, M. O., Lönnqvist, J. K., Standerskjold-Nordenstam, C.-G., Narr, K. L., Khaledy, M., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052023499 · Cited by 315 · see citing works
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · see citing works
Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept
Schizophrenia Working Group of the Psychiatric Genomics Consortium, Franke, B., Enigma Consortium, Stein, J. L., Ripke, S., Anttila, V., Hibar, D. P., van Hulzen, K. J. E., Arias-Vasquez, A., Smoller, J. W., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4228 · Cited by 216 · see citing works
Orešič, M., Seppänen‐Laakso, T., Sun, D., Tang, J. P., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P. M., et al. (2012) · eScholarship (California Digital Library) · Cited by 168 · see citing works
Metabolome in schizophrenia and other psychotic disorders: a general population-based study
Orešič, M., Tang, J. P., Seppänen‐Laakso, T., Mattila, I. M., Saarni, S. E., Saarni, S. I., Lönnqvist, J. K., Sysi‐Aho, M., Hyötyläinen, T., Perälä, J., et al. (2011) · Genome Medicine · doi:10.1186/gm233 · Cited by 158 · see citing works
Naz, S., Gallart‐Ayala, H., Reinke, S. N., Mathon, C., Blankley, R. T., Chaleckis, R., & Wheelock, C. E. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b00925 · Cited by 143 · see citing works
Martins-de-Souza, D., Harris, L. W., Guest, P. C., & Bahn, S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3459 · Cited by 134 · see citing works
The Neuroproteomics of Schizophrenia
English, J. A., Pennington, K., Dunn, M. J., & Cotter, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.031 · Cited by 127 · see citing works
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127 · see citing works
Zhou, J., Li, Y., Chen, X., Zhong, L., & Yin, Y. (2016) · Talanta · doi:10.1016/j.talanta.2016.11.048 · Cited by 76 · see citing works
Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia
Wood, P. L., Unfried, G., Whitehead, W. F., Phillipps, A., & Wood, J. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.032 · Cited by 50 · see citing works
Velásquez, E., Nogueira, F. C. S., Velásquez, I., Schmitt, A., Falkai, P., Domont, G. B., & Martins‐de‐Souza, D. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00422 · Cited by 33 · see citing works
Poo, S. X. W., & Agius, M. A. (2015) · PubMed · Cited by 8 · see citing works
Orešič, M., Seppänen-Laakso, T., Sun, D., Tang, J., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P., et al. (2012) · Genome Medicine · doi:10.1186/gm300 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tkachev, A., Stekolshchikova, E., Vanyushkina, A., Zhang, H., Morozova, A. Y., Zozulya, S. A., Kurochkin, I., Anikanov, N. A., Egorova, A., Yushina, E., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.4350 · Cited by 78 · see citing works
Population Pharmacokinetics of Clozapine: A Systematic Review
Albitar, O., Harun, S. N., Zainal, H., Ibrahim, B., & Ghadzi, S. M. S. (2020) · BioMed Research International · doi:10.1155/2020/9872936 · Cited by 59 · see citing works
SWATH-MS for metabolomics and lipidomics: critical aspects of qualitative and quantitative analysis
Raetz, M., Bonner, R. F., & Gérard Hopfgartner, D. (2020) · Metabolomics · doi:10.1007/s11306-020-01692-0 · Cited by 58 · see citing works
Wang, L., Su, B., Zeng, Z., Li, C., Zhao, X., Lv, W., Xuan, Q., Ouyang, Y., Zhou, L., Yin, P., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02377 · Cited by 47 · see citing works
Zhou, J., Ji, N., Wang, G., Zhang, Y., Song, H., Yuan, Y., Yang, C., Jin, Y., Zhang, Z., Zhang, L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104097 · Cited by 42 · see citing works
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works
The impact of quetiapine on the brain lipidome in a cuprizone-induced mouse model of schizophrenia
Zhou, C., Xue, S., Xue, F., Liu, L., Liu, J.-C., Ma, Q., Qin, J., Tan, Q.-R., Wang, H., & Peng, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110707 · Cited by 22 · see citing works
Zhou, C., Cai, M., Wang, Y., Wu, W.-J., Yin, Y., Wang, X., Hu, G., Wang, H., Tan, Q., & Peng, Z. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.706786 · Cited by 16 · see citing works
Couttas, T. A., Jieu, B., Rohleder, C., & Leweke, F. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.885904 · Cited by 17 · see citing works
Metabolomics, Lipidomics, and Antipsychotics: A Systematic Review
Burghardt, K. J., Kajy, M., Ward, K. M., & Burghardt, P. R. (2023) · Biomedicines · doi:10.3390/biomedicines11123295 · Cited by 16 · see citing works
Screening for depression in the general population through lipid biomarkers
Tkachev, A., Stekolshchikova, E., Golubova, A., Serkina, A., Morozova, A. Y., Zorkina, Y., Riabinina, D., Golubeva, E., Ochneva, A., Savenkova, V., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105455 · Cited by 15 · see citing works
Discovery of biological markers for schizophrenia based on metabolomics: a systematic review
Yao, G., Zeng, J., Huang, Y. C., Lu, H., Ping, J., Wan, J., Jiang, T., Deng, F., Li, C., Liu, X., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1540260 · Cited by 14 · see citing works
Canfrán-Duque, A., Pastor, Ó., García-Seisdedos, D., Molina, Y. L., Babiy, B., Lerma, M., Sánchez-Castellano, C., Martínez-Botas, J., Gómez-Coronado, D., Lasunción, M. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083919 · Cited by 11 · see citing works
Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia
Tkachev, A., Stekolshchikova, E., Anikanov, N., Zozulya, S., Barkhatova, A., Klyushnik, T., & Petrova, D. (2021) · Biomolecules · doi:10.3390/biom11050720 · Cited by 11 · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
Wang, X., Xie, J., Ma, H., Li, G., Li, M., Li, S., Sun, X., Zhao, Y., Sun, W., Yang, S., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2271965 · Cited by 11 · see citing works
Spathopoulou, A., Sauerwein, G. A., Marteau, V., Podlesnic, M., Lindlbauer, T., Kipura, T., Hotze, M., Gabassi, E., Kruszewski, K., Koskuvi, M., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02568-8 · Cited by 10 · see citing works
Altered lipidomics biosignatures in schizophrenia: A systematic review
Messinis, A., Panteli, E., Paraskevopoulou, A., Zymarikopoulou, A.-K., & Filiou, M. D. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.043 · Cited by 10 · see citing works
Wu, S., Panganiban, K. J., Lee, J., Li, D., Smith, E. C. C., Maksyutynska, K., Humber, B. E., Ahmed, T., Agarwal, S. M., Ward, K. M., et al. (2024) · Metabolites · doi:10.3390/metabo14090475 · Cited by 11 · see citing works
Zapata, R. C., Rosenthal, S. B., Fisch, K. M., Dao, K., Jain, M., & Osborn, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-75624-2 · Cited by 9 · see citing works
Ceramides: Shared Lipid Biomarkers of Cardiovascular Disease and Schizophrenia
Tkachev, A., Stekolshchikova, E., Morozova, A. Y., Anikanov, N. A., Zorkina, Y., Alekseyeva, P. N., Khobta, E. B., Andreyuk, D., Zozulya, S. A., Barkhatova, A., et al. (2021) · Consortium Psychiatricum · doi:10.17816/cp101 · Cited by 8 · see citing works
Intra- and inter-individual variation of the human lipidome
Anh, N. H., Beyene, H. B., Mocciaro, G., Hahnefeld, L., Lamichhane, S., Fabritius, M., Avela, H. F., Wang, Y., Dickens, A. M., Gurke, R., et al. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118368 · Cited by 7 · see citing works
The identification of novel schizophrenia-related metabolites using untargeted lipidomics
Shi, M., Du, X., Jia, Y., Zhang, Y., Jia, Q., Zhang, X., & Zhu, Z. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae160 · Cited by 6 · see citing works
Jieu, B., Sykorova, E. B., Rohleder, C., Marcolini, E., Hoffmann, A., Koethe, D., Leweke, F. M., & Couttas, T. A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116005 · Cited by 6 · see citing works
Plasma and Serum LC-MS Lipidomic Fingerprints of Bipolar Disorder and Schizophrenia
Takić, M. M., Jovanović, V. B., Marković, S., Miladinović, Z. P., Jadranin, M. B., Krstić, G., Miljević, Č., Tešević, V., & Mandić, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136134 · Cited by 4 · see citing works
LC–HRMS Lipidomic Fingerprints in Serbian Cohort of Schizophrenia Patients
Marković, S., Jadranin, M. B., Miladinović, Z. P., Gavrilović, A., Avramović, N., Takić, M. M., Tasić, L., Tešević, V., & Mandić, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910266 · Cited by 4 · see citing works
Wang, S., Dong, Y., Qiu, Y., Sun, X., Jiang, C., Su, Q., Li, M., & Li, J. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.016 · Cited by 4 · see citing works
Blood Plasma Lipid Alterations Differentiating Psychotic and Affective Disorder Patients
Golubova, A., Stekolshchikova, E., Гареева, А. Э., Akhmerova, I. Y., Тимербулатов, И. Ф., Zakurazhnaya, V., Riabinina, D., Reznik, A. M., Morozova, A. Y., Andreyuk, D., et al. (2025) · Biomolecules · doi:10.3390/biom15091296 · Cited by 3 · see citing works
Dong, Y., Wang, S., Qiu, Y., Su, Q., Sun, X., Li, M., & Li, J. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107711 · Cited by 3 · see citing works
Baker, C. E., Marta, A. G., Zimmerman, N. D., Korade, Ž., Mathy, N. W., Wilton, D., Simeone, T. A., Kochvar, A. P., Kramer, K. L., Stessman, H. A. F., et al. (2024) · Biomolecules · doi:10.3390/biom14080914 · Cited by 3 · see citing works
Discrimination of Bipolar Disorder and Schizophrenia Patients Based on LC-HRMS Lipidomics
Janković, M. R., Avramović, N., Miladinović, Z., Jadranin, M. B., Takić, M. M., Krstić, G., Gavrilović, A., Miljević, Č., Pantović, M., Andrić, Z., et al. (2026) · Metabolites · doi:10.3390/metabo16010069 · Cited by 2 · see citing works
Proteomics and Schizophrenia: The Evolution of a Great Partnership
Smith, B. J., Carregari, V. C., & Martins‐de‐Souza, D. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-97182-3_10 · Cited by 2 · see citing works
Multiomics Approaches in Psychiatric Disorders
Schulte, E. C., Kohshour, M. O., Tkachev, A., Khaitovich, P., & Schulze, T. G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_30-1
Multiomics Approaches in Psychiatric Disorders
Schulte, E. C., Kohshour, M. O., Tkachev, A., Khaitovich, P., & Schulze, T. G. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_30
Weber, A., Papiol, S., Tkachev, A., Senner, F., Reich‐Erkelenz, D., Navarro‐Flores, A., Kohshour, M. O., Heilbronner, U., Heilbronner, M., Budde, M., et al. (2026) · medRxiv · doi:10.64898/2026.01.06.26343451
Plasma Lipid Alterations Track Multidimensional Psychosis Severity Across Diagnostic BoundariesPreprint
Thanabalasingam, A., Wiegand, A., Meijer, J., Dwyer, D., Schulte, E. C., & Study, T. P. (2026) · medRxiv · doi:10.64898/2026.02.24.26346956
Peng, X.-Q., Liu, B., Meng, W., Huang, J., Zhang, Q., Chen, L., Li, K., Tong, H. H. Y., Zhang, X., Zhang, J., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111984
- Authors
- Yan, L., Zhou, J., Wang, D., Si, D., Liu, Y., Zhong, L., & Yin, Y.
- Affiliations
- Peking University (CN)
- Corresponding author
- Zhong, Lijun
- Yin, Yuxin
- Venue
- Metabolomics
- Published
- 2018-06
- Volume
- 14
- Issue
- 6
- Pages
- 80-80
- ISSN
- 1573-3882 (ISSN-L)
- 1573-3890
- OpenAlex
- W2805491735
- Cited by
- 36
- References
- 31
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 10 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 4 · 2018: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Metabolomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81430056)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- schizophrenia, plasma lipidomics, antipsychotic drugs, lipid dysregulation, sphingomyelin, acylcarnitines, ceramide, lipid biomarkers, schizophrenia pathogenesis, antipsychotic adverse effects
- MeSH terms
- Adult, Chromatography, High Pressure Liquid, Female, Humans, Lipids, Male, Middle Aged, Schizophrenia, Antipsychotic Agents, Biomarkers, Case-Control Studies, Age of Onset, Tandem Mass Spectrometry, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
